Semaglutide Reconstitution Calculator

Yes. Subcutaneous Ozempic is approved for type 2 diabetes; Wegovy 2.4 mg weekly is approved for chronic weight management (BMI ≥30, or ≥27 with ≥1 weight-related comorbidity) and, since 2024, for cardiovascular risk reduction in adults with established CVD and obesity/overweight. Oral Wegovy is the first oral GLP-1 receptor agonist approved for weight management (50 mg; 25 mg also available in the program). Wegovy HD 7.2 mg is approved for adults who tolerated 2.4 mg for ≥4 weeks and need additional loss. Ozempic also carries the first renal indication in T2D + CKD; Wegovy holds MASH accelerated approval (practitioner consensus).

Subcutaneous: start 0.25 mg once weekly ×4 weeks, then 0.5 mg ×4 weeks, then 1.0 mg; obesity titration continues 1.7 mg → 2.4 mg (community protocol). Slow escalation minimizes GI intolerance, which is dominated by nausea up to ~20% and diarrhea up to 13%. Off-label Ozempic titrated to 1.0 mg weekly produced 9.8% mean weight loss at 6 months in 20 patients. Oral: 3 → 7 → 14 mg daily for diabetes; 25 → 50 mg daily for weight management, swallowed fasted with ≤120 mL water ≥30 min before food (practitioner consensus). Dosing errors cluster at initiation/escalation (an accidental 9.6 mg injection caused 7 days of self-limited dysesthesia).

Subcutaneous 2.4 mg weekly gave −14.9% vs −2.4% placebo at 68 weeks (STEP 1). Oral 25 mg daily achieves exposure overlapping SC 2.4 mg in 82% of users and is modeled to yield 16.3% (trial estimand) / 14.7% (policy estimand) weight loss without diabetes. Oral trades daily fasting for no injections; SC offers once-weekly dosing and supports the highest approved doses (2.4/7.2 mg). Choose by lifestyle and needle tolerance (practitioner consensus).

Head-to-head meta-analysis (10 studies, 41,381 participants): tirzepatide beats semaglutide by −4.28 percentage points (MD −4.43 kg) with higher odds of ≥10/15/20% loss. A network meta-analysis ranks tirzepatide 15 mg (−17.97%) and CagriSema (−17.84%) above semaglutide 7.2 mg (−14.66%). Response is variable: 26% of real-world Wegovy users are super-responders (>15% in 1 year) vs 34% for Zepbound; roughly 40–42% are moderate (5–15%) responders across brands (observational). Lower doses still work in routine practice (see above).

Thyroid cancer: <1% across 10 RCTs (14,550 participants), no significant signal. Eyes: FAERS shows a nonarteritic anterior ischemic optic neuropathy signal: Wegovy ROR 74.89, Ozempic 18.81, higher in men; rare but vision-threatening (pharmacovigilance). Mood: pooled depression RR 1.25 (95% CI 0.95–1.65), no significant increase vs placebo/comparator, though heterogeneity is high. Bone: in obesity + T2D, semaglutide initiation was associated with lower major osteoporotic fracture risk (HR 0.69–0.84 vs comparators); no association in obesity without T2D (observational). GI effects are the dominant issue and usually fade with slow titration.

Weight loss can restore ovulation: adding semaglutide to metformin raised pregnancy rate to 35% vs 15% (one RCT, p<0.05). Unplanned pregnancies during GLP-1 use are widely reported, review contraception at initiation (practitioner consensus). Human pregnancy safety data are inadequate; stop semaglutide ≥2 months before planned conception (5 half-lives plus margin). Postmenopausal bleeding occurred in a case at 0.5 mg weekly and resolved after discontinuation.

Treat obesity as a chronic condition: semaglutide works while taken. In STEP 4, patients switched to placebo regained 6.9% while continuers lost a further 7.9% over 48 weeks; most lost weight returns after stopping. UK NICE caps funded treatment at 2 years. Real-world persistence is the practical ceiling (~53% still on GLP-1 at 1 year; median duration ~240 days) (observational).

Unopened pens: refrigerate 2–8°C; in-use pens stay at room temperature up to 28 days, protected from heat/freezing (community protocol). The long half-life (168 h) is forgiving: a missed weekly dose can be injected up to 2 days late without major glycemic or weight consequence; if more than 2 days late, skip and resume on schedule (mechanistic) (practitioner consensus). Check the pen window before injecting, and never use contents that appear cloudy or discolored (community protocol).